Melanoma/Skin Cancer News

Genomic testing continues to provide oncologists with a wealth of meaningful, treatment-guiding information for a growing number of cancers.

A tool designed to assess skin cancer risk in solid organ transplant recipients proved to be efficacious in independent populations outside of the one used in its creation, according to a study.

The FDA granted de novo classification to the SeCore CDx HLA Sequencing System for use as a companion diagnostic with Kimmtrak for metastatic or unresectable uveal melanoma, according to a Thermo Fisher Scientific press release.

Second primary melanomas are more likely to develop in patients with more nevi and a high genetic predisposition to melanoma, according to a study.

PHILADELPHIA — Patients with rheumatic diseases and previous malignancy do not demonstrate a higher cancer risk with TNF inhibitors vs. other biologic and targeted synthetic DMARDs, according to data presented at ACR Convergence 2022.

A dramatic rise in global incidence of early-onset cancers over the past 30 years may be related in part to increased exposure to risk factors at a young age, according to study results published in Nature Reviews Clinical Oncology,

The presence of microsatellites was associated with poorer overall survival in a retrospective cohort of patients with cutaneous melanoma, according to a study.

Fecal microbiota transplant from healthy donors may lower primary resistance to immunotherapy with anti-PD-1 agents among patients with advanced or metastatic melanoma, results of the phase 1 MIMic trial showed.

The sequence of surgery and immunotherapy affects outcomes for patients with melanoma, according to a speaker at Chemotherapy Foundation Symposium.

The FDA granted orphan drug designation to AVS100 for the treatment of stage IIB through stage IV melanoma, according to the agent’s manufacturer.